Pharmaceuticals - Czechia

  • Czechia
  • Czechia is expected to witness a significant growth in revenue within the Pharmaceuticals market, reaching an estimated value of CZK US$2,137.00m by 2024.
  • Among the different markets, Oncology Drugs is projected to be the largest, with a market volume of CZK US$364.70m in the same year.
  • Over the forecast period from 2024 to 2029, the market is anticipated to display a steady annual growth rate (CAGR 2024-2029) of 4.40%, resulting in a market volume of CZK US$2,650.00m by 2029.
  • In comparison to other countries, United States is expected to generate the highest revenue within the Pharmaceuticals market, estimated at US$630.30bn by 2024.
  • This clearly demonstrates the dominance of the United States in the global pharmaceutical industry.
  • Czechia's pharmaceutical market is witnessing a surge in demand for innovative biologic drugs, driven by a growing aging population and increasing healthcare expenditure.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Pharmaceuticals market in Czechia has been experiencing steady growth in recent years.

Customer preferences:
Czechia has a well-established healthcare system that provides universal coverage to its citizens. As a result, there is a high demand for pharmaceutical products in the country. Customers in Czechia prefer high-quality and affordable drugs that are easily accessible. They also tend to favor generic drugs over branded ones.

Trends in the market:
The pharmaceuticals market in Czechia has been growing steadily over the past few years. This growth can be attributed to several factors, including an increase in the demand for pharmaceutical products, the rise in chronic diseases, and the aging population. The market has also been driven by the increasing number of clinical trials being conducted in the country.

Local special circumstances:
Czechia has a well-developed pharmaceutical industry, with several local manufacturers producing a wide range of drugs. The country has a favorable regulatory environment that encourages the development and production of pharmaceutical products. Additionally, the country's central location in Europe makes it an attractive market for pharmaceutical companies looking to expand their operations in the region.

Underlying macroeconomic factors:
The Czech economy has been growing steadily over the past few years, with a strong focus on innovation and technology. The country has a highly educated workforce, which has contributed to the growth of the pharmaceutical industry. The government has also been investing in the healthcare sector, which has helped to drive the growth of the pharmaceutical market. Overall, the favorable economic and regulatory environment in Czechia is expected to continue to drive the growth of the pharmaceutical industry in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Next generation therapy
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)